Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Accumulated Expenses (2016 - 2025)

Orthofix Medical's Accumulated Expenses history spans 16 years, with the latest figure at $27.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 38.44% year-over-year to $27.0 million, compared with a TTM value of $27.0 million through Dec 2025, down 38.44%, and an annual FY2025 reading of $27.0 million, down 38.44% over the prior year.
  • Accumulated Expenses for Q4 2025 was $27.0 million at Orthofix Medical, down from $43.9 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $43.9 million in Q4 2024, with the low at $7.0 million in Q4 2023.
  • Average Accumulated Expenses over 5 years is $18.9 million, with a median of $9.6 million recorded in 2022.
  • Year-over-year, Accumulated Expenses soared 527.13% in 2024 and then plummeted 38.44% in 2025.
  • Tracing OFIX's Accumulated Expenses over 5 years: stood at $7.2 million in 2021, then skyrocketed by 34.4% to $9.6 million in 2022, then fell by 27.17% to $7.0 million in 2023, then soared by 527.13% to $43.9 million in 2024, then tumbled by 38.44% to $27.0 million in 2025.
  • Per Business Quant, the three most recent readings for OFIX's Accumulated Expenses are $27.0 million (Q4 2025), $43.9 million (Q4 2024), and $7.0 million (Q4 2023).